Balancing transparency and access: Controversy over confidential medicinal product pricing in Spain

The debate over the confidentiality versus transparency of net medicinal product prices has intensified in Spain, particularly following recent legislative and judicial developments. At stake is a fundamental policy dilemma: whether publicizing “real prices” (i.e., net prices) strengthens accountability and fairness, or whether it risks delaying or limiting patient access to innovative treatments. This tension has become especially visible in the context of new amendments promoted by PSOE and SUMAR parliamentary groups, and the parallel legal actions led by the civil society organization Civio.

The Spanish Ministry of Health has defended the need to preserve confidentiality of net prices and reimbursement conditions for innovative medicinal products. Recent amendments seek to reinforce this confidentiality by explicitly extending it to reimbursement agreements and the prices paid in public procurement. The Ministry justifies this approach on pragmatic grounds: in a global market influenced by international reference pricing and external policies such as the U.S. “Most Favored Nation” policy, disclosing lower net prices could discourage pharmaceutical companies from launching new medicinal products early in Spain, potentially delaying patient access.

Civio, however, criticizes both the substance and the legislative strategy of these amendments. The organization argues that embedding such a reform within a disability law bypasses proper parliamentary scrutiny and aims to pre-empt a pending ruling by the Supreme Court on whether these prices should be public. Substantively, Civio contends that the proposed wording goes far beyond protecting commercially sensitive information submitted by companies, effectively making the outcome of public decisions—i.e., how much the health care system pays for medicinal products—secret by law. This, they argue, could introduce a significant exception within public procurement practices, potentially affecting existing transparency principles and the level of public oversight over pharmaceutical spending.

Ultimately, the debate illustrates a broader and unresolved conflict between two legitimate public values: transparency in the use of public funds, and equitable, timely access to medicinal products. The Ministry prioritizes access under conditions of uncertainty, opting for confidentiality as a precautionary measure, while organizations like Civio emphasize the democratic necessity of transparency and legal accountability. As the Spanish Supreme Court prepares to rule on this issue, and Parliament debates the proposed amendments, Spain faces a defining moment in determining how to balance these competing principles in its pharmaceutical policy. The uncertain outcome of this process could have far-reaching implications, not only for pharmaceutical companies' pricing and launch strategies, but also for the foundational principles shaping pharmaceutical policy as a whole.

For any questions or further discussion on these issues, feel free to contact either of the authors of this alert.

Authored by Fernando Calancha and Álvaro Abad.